Triple-negative and basal-like breast cancer: implications for oncologists.
作者信息
Lachapelle J, Foulkes W D
机构信息
Department of Pathology, McGill University, Montreal, QC.
出版信息
Curr Oncol. 2011 Aug;18(4):161-4. doi: 10.3747/co.v18i4.824.
Abstract
摘要
相似文献
1
Triple-negative and basal-like breast cancer: implications for oncologists.
Curr Oncol. 2011 Aug;18(4):161-4. doi: 10.3747/co.v18i4.824.
2
Clinical significance of basal-like subtype in triple-negative breast cancer.
Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.
3
Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Tumour Biol. 2020 Jan;42(1):1010428319901052. doi: 10.1177/1010428319901052.
4
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Breast Cancer Res Treat. 2015 Apr;150(3):479-86. doi: 10.1007/s10549-015-3338-y. Epub 2015 Mar 18.
5
Triple-negative breast cancer: current state of the art.
Tumori. 2010 Nov-Dec;96(6):875-88.
6
Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities.
Breast Cancer (Auckl). 2018 Aug 24;12:1178223418792247. doi: 10.1177/1178223418792247. eCollection 2018.
7
Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
J Neurooncol. 2011 Dec;105(3):547-53. doi: 10.1007/s11060-011-0616-3. Epub 2011 Jun 9.
8
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.
9
Management of primary and metastatic triple negative breast cancer: perceptions of oncologists from India.
Indian J Cancer. 2011 Apr-Jun;48(2):158-64. doi: 10.4103/0019-509X.82874.
10
ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
Breast Cancer Res Treat. 2017 Jun;163(3):475-484. doi: 10.1007/s10549-017-4216-6. Epub 2017 Mar 27.
引用本文的文献
1
Breastfeeding attributable fraction of triple negative breast cancer in the US.
NPJ Breast Cancer. 2025 May 7;11(1):40. doi: 10.1038/s41523-025-00755-6.
2
Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies.
Cancers (Basel). 2024 Jul 7;16(13):2481. doi: 10.3390/cancers16132481.
3
Application of single-cell sequencing to the research of tumor microenvironment.
Front Immunol. 2023 Oct 27;14:1285540. doi: 10.3389/fimmu.2023.1285540. eCollection 2023.
4
Growth Inhibition, Caspase-Dependent Apoptosis, and S and G2/M Phase Arrest in Breast Cancer Cells Induced by Fluorine-Incorporated Gold I Compound, Ph3PAu[SC(OMe)=NC6H4F-3].
Int J Breast Cancer. 2022 Jul 21;2022:7168210. doi: 10.1155/2022/7168210. eCollection 2022.
5
The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.
Transl Cancer Res. 2021 Mar;10(3):1193-1203. doi: 10.21037/tcr-20-1760.
6
Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies.
Front Oncol. 2021 Jun 24;11:674354. doi: 10.3389/fonc.2021.674354. eCollection 2021.
7
Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks.
Mol Ther Nucleic Acids. 2021 Jan 1;23:682-690. doi: 10.1016/j.omtn.2020.12.018. eCollection 2021 Mar 5.
8
Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype.
Front Oncol. 2020 Dec 23;10:580345. doi: 10.3389/fonc.2020.580345. eCollection 2020.
9
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
BMC Cancer. 2019 Jul 15;19(1):695. doi: 10.1186/s12885-019-5908-6.
10
Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.
BMC Cancer. 2019 Apr 3;19(1):307. doi: 10.1186/s12885-019-5503-x.
本文引用的文献
1
A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis.
Curr Oncol. 2011 Aug;18(4):191-6. doi: 10.3747/co.v18i4.815.
2
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.
Cell. 2011 Mar 4;144(5):703-18. doi: 10.1016/j.cell.2011.02.003.
3
Uncovering a tumor suppressor for triple-negative breast cancers.
Cell. 2011 Mar 4;144(5):638-40. doi: 10.1016/j.cell.2011.02.030.
4
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
Clin Cancer Res. 2010 Dec 15;16(24):6100-10. doi: 10.1158/1078-0432.CCR-10-1533.
5
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
Breast Cancer Res Treat. 2011 Feb;125(3):755-65. doi: 10.1007/s10549-010-1251-y. Epub 2010 Dec 3.
6
Triple-negative breast cancer.
N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389.
7
Synthetic lethal approaches to breast cancer therapy.
Nat Rev Clin Oncol. 2010 Dec;7(12):718-24. doi: 10.1038/nrclinonc.2010.172. Epub 2010 Oct 19.
8
Triple-negative breast cancer: disease entity or title of convenience?
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28.
9
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.
10
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.
Zotero 插件